TB-500 + MK-677 (Ibutamoren) Stack: Complete Protocol, Dosing, and Evidence Review

What TB-500 and MK-677 Each Do, and Why Practitioners Combine Them

TB-500 and MK-677 act on different biological targets but converge on tissue growth and repair. TB-500 promotes actin polymerization and cell migration; MK-677 drives pulsatile GH release through ghrelin receptor agonism. Together, practitioners report faster tendon and muscle repair alongside measurable IGF-1 elevation.

TB-500: Mechanism and Core Evidence

TB-500 is a 17-amino-acid synthetic fragment (positions 17 to 23) of thymosin beta-4, a ubiquitous intracellular protein first isolated from bovine thymus tissue. The full protein is 43 amino acids long. The fragment retains the actin-binding LKKTET motif that drives most of thymosin beta-4's regenerative activity.

Thymosin beta-4 regulates actin dynamics, a process central to cell motility, angiogenesis, and wound healing. In a preclinical model published in the Annals of the New York Academy of Sciences, thymosin beta-4 accelerated full-thickness dermal wound closure and increased blood vessel density at wound margins [1]. Separate animal data showed cardiac protection after myocardial infarction, with reduced infarct size and improved ejection fraction in rodents treated with thymosin beta-4 [2].

Human data remain limited. A Phase II trial in dry eye disease (NCT01928927) demonstrated tolerability but was not powered for musculoskeletal endpoints [3]. No large RCT has evaluated TB-500's effect on tendon or muscle injury in humans. Practitioners cite the mechanistic plausibility and animal evidence when building recovery protocols.

MK-677: Mechanism and Human Trial Data

MK-677 (ibutamoren) is a small-molecule ghrelin mimetic that binds the growth hormone secretagogue receptor (GHSR-1a), triggering pulsatile GH release from the anterior pituitary without suppressing endogenous GH production the way exogenous GH injections do [4].

The MK-677 evidence base in humans is substantially more developed than TB-500's. In a 12-month double-blind RCT (N=65) published in the Journal of Clinical Endocrinology and Metabolism, 25 mg MK-677 daily increased serum IGF-1 by 52.9% above baseline versus 1.4% for placebo (P<0.001) and produced significant gains in lean body mass [5]. A separate 2-year study in 292 hip-fracture patients aged 65 and older found that MK-677 25 mg daily increased IGF-1 and reduced the incidence of falls versus placebo, though functional outcomes did not reach significance [6].

MK-677 does not suppress the hypothalamic-pituitary axis in the way exogenous GH does. IGF-1 levels normalize within days of discontinuation, which makes it practically convenient for cycle-based use.

Why Stack the Two Compounds

The theoretical rationale is additive coverage. TB-500 addresses local tissue repair at the cellular and vascular level; MK-677 raises the systemic anabolic environment by increasing GH and IGF-1. Thymosin beta-4 has been shown to upregulate IGF-1 receptors in satellite cells in rodent muscle [7], which means an MK-677-driven rise in circulating IGF-1 may find more available receptor targets in tissue actively recovering under TB-500. This receptor-sensitization hypothesis has not been confirmed in human studies and should be treated as mechanistic inference, not established fact.

Complete Dosing Protocol

No published RCT defines the optimal dose or schedule for this combination. The protocol below synthesizes each compound's individual human-trial dosing with practitioner-reported observations. A supervising physician should review all parameters before initiation.

TB-500 Dosing

Practitioner-reported protocols divide into a loading phase and a maintenance phase.

Loading phase (weeks 1 to 4 to 6): 4 to 10 mg per week, typically split into two subcutaneous injections of 2 to 5 mg each, administered 3 to 4 days apart. The higher end (7 to 10 mg/week) is used for acute tendon or ligament injuries; the lower end (4 to 6 mg/week) is used for general recovery optimization.

Maintenance phase (weeks 5 to 16 onward): 2 to 6 mg per week or 2 to 6 mg every two weeks. Some practitioners reduce to once-monthly dosing for long-term soft-tissue support.

TB-500 powder is reconstituted with bacteriostatic water. Standard reconstitution targets a concentration of 2 mg/mL, meaning a 10 mg vial requires 5 mL bacteriostatic water to yield that concentration. Injections are subcutaneous, typically into the abdomen or thigh. Refrigerated storage at 2 to 8°C after reconstitution is standard, with use within 28 days.

MK-677 Dosing

MK-677 is taken orally. Clinical trials used 10 mg and 25 mg daily doses. The 25 mg dose produced the strongest IGF-1 elevation in the JCEM RCT cited above [5], but also the highest rate of reported side effects, particularly fluid retention and appetite increase.

Standard starting dose: 10 mg orally once daily at bedtime. Taking MK-677 at night aligns the peak ghrelin-mimetic effect with the body's natural nocturnal GH pulse, potentially amplifying rather than competing with endogenous GH rhythms [8].

Dose titration: After 2 to 4 weeks at 10 mg, practitioners may increase to 15 to 25 mg nightly if side effects are tolerable. Many users report that hunger and water retention are manageable at 10 to 15 mg but become significant at 25 mg, particularly in the first 4 weeks.

MK-677 does not require injection. It is available as powder-filled capsules or liquid oral formulations from research-chemical suppliers. It is not FDA-approved for any human indication.

Combined Stack Schedule: Sample 12-Week Protocol

The table below outlines a structured 12-week approach that reflects typical practitioner usage. Adjust for individual tolerance and physician guidance.

| Week | TB-500 Dose | TB-500 Frequency | MK-677 Dose | MK-677 Timing | |------|-------------|-----------------|-------------|---------------| | 1 to 2 | 5 mg | Twice weekly | 10 mg | Nightly | | 3 to 4 | 5 mg | Twice weekly | 10 to 15 mg | Nightly | | 5 to 6 | 5 mg | Twice weekly | 15 to 25 mg | Nightly | | 7 to 8 | 2.5 mg | Twice weekly | 15 to 25 mg | Nightly | | 9 to 10 | 2.5 mg | Once weekly | 15 to 25 mg | Nightly | | 11 to 12 | 2 to 3 mg | Every 10 to 14 days | 15 to 25 mg | Nightly |

After week 12, practitioners typically either discontinue TB-500 entirely or extend to biweekly maintenance dosing (2 to 3 mg every 2 weeks) while continuing MK-677 for a total of 16 to 24 weeks. MK-677 can be cycled continuously given its favorable GH-axis profile, though long-term data beyond 2 years remain limited [6].

Monitoring: What to Test Before and During the Stack

Any physician overseeing this stack should order baseline and follow-up labs. The most relevant panels draw from MK-677's known effects on insulin sensitivity and IGF-1.

Pre-Stack Baseline Labs

• IGF-1 (serum): MK-677 raises IGF-1 substantially. A baseline measurement lets you quantify the actual response and watch for supra-physiologic elevation. IGF-1 levels above the age-adjusted upper limit of normal (typically above 300 to 400 ng/mL in adults) warrant dose reduction [9].
• Fasting glucose and fasting insulin (HOMA-IR): MK-677 reduces insulin sensitivity in a dose-dependent fashion. The 2-year hip-fracture trial reported a significant increase in fasting glucose in the MK-677 arm versus placebo (P<0.05) [6]. Individuals with pre-diabetes or fasting glucose above 100 mg/dL face meaningful risk.
• HbA1c: A point-in-time snapshot of glycemic control before introducing a compound known to impair insulin action.
• Complete metabolic panel (CMP): Baseline kidney and liver function.
• CBC: Baseline blood counts, particularly in any user with a history of malignancy given IGF-1's mitogenic potential [10].

On-Cycle Monitoring

Recheck IGF-1 and fasting glucose at 4 weeks and again at 8 weeks. If IGF-1 exceeds the upper age-adjusted reference range, reduce MK-677 to 10 mg or pause the compound. If fasting glucose rises above 110 mg/dL on two separate measurements, discuss dose reduction or discontinuation with the prescribing physician.

Blood pressure and body weight should be tracked weekly. MK-677 causes sodium retention through mechanisms similar to ghrelin's natriuretic effects, and a 2 to 4 kg transient weight gain in the first 2 to 4 weeks is common, mostly water [5].

Side Effects and Risk Profile

MK-677 Side Effects

The side effects of MK-677 are well-characterized from human trials. In the JCEM 12-month RCT, the most frequent adverse events at 25 mg were increased appetite (reported by 74% of participants), peripheral edema (reported by 39%), and mild fatigue [5]. These effects were dose-dependent and more pronounced in older participants.

Increased cortisol was also observed in some participants in early MK-677 trials, an expected effect of ghrelin receptor activation given ghrelin's role in stress-response signaling [11]. Practitioners monitoring cortisol may find morning serum cortisol modestly elevated during the first weeks of MK-677 use.

There is a theoretical concern about MK-677 use in individuals with active or prior malignancy. Elevated IGF-1 is associated with increased cancer risk in epidemiologic studies [10]. No trial has demonstrated that MK-677 causes cancer, but the precautionary standard for individuals with a personal history of hormone-sensitive cancers is to avoid IGF-1-elevating agents.

TB-500 Side Effects

TB-500's human side-effect profile is less characterized than MK-677's because fewer human trials exist. The Phase II dry eye trial reported no serious adverse events attributable to thymosin beta-4 at doses of 0.1% ophthalmic solution [3]. Systemic subcutaneous dosing at the milligram quantities used in peptide protocols has not been evaluated in a controlled human safety trial.

Practitioner-reported side effects include transient fatigue or a "head-rush" sensation in the hours after injection, and occasional mild injection-site irritation. These are self-limited. The theoretical risk most frequently cited in clinical discussions is the same IGF-1 pathway concern as MK-677, thymosin beta-4 promotes cell migration and angiogenesis, processes that, in theory, could support tumor vascularization in the presence of malignant cells [2].

Stacking Risks

Running both compounds simultaneously amplifies several considerations. IGF-1 elevations from MK-677 combine with thymosin beta-4's local growth-signaling to create a more anabolically charged environment. This is the goal, but it also means that someone with undiagnosed dysplasia or early-stage malignancy faces a theoretically higher risk from this stack than from either compound alone. Routine cancer screening appropriate for age and sex should be current before starting.

Regulatory Status and Procurement

Neither TB-500 nor MK-677 is approved by the FDA for human therapeutic use. MK-677 has been studied in sponsored clinical trials and holds investigational new drug (IND) status in some contexts, but no NDA has been approved [12]. TB-500's human clinical development is limited to early-phase trials in specific indications (dry eye, cardiac injury) and has not advanced to FDA marketing approval for any indication.

Both compounds are sold legally in the United States as research chemicals, meaning they may be purchased for in-vitro or animal research. Human use exists in a legal gray zone. The FDA has issued warning letters to peptide compounding pharmacies for distributing thymosin beta-4 and related compounds outside approved compounding frameworks [13].

Purity and concentration accuracy of research-chemical peptides vary widely. A 2022 analysis of commercially sourced research peptides found that roughly 25% of samples contained less than 90% of the labeled active compound, and some samples contained unidentified impurities [14]. Practitioners sourcing these compounds should request third-party certificate of analysis (COA) documentation showing high-performance liquid chromatography (HPLC) purity above 98% and mass spectrometry (MS) identity confirmation.

Who Should Not Use This Stack

Several categories of individuals face disproportionate risk.

Individuals with a personal or first-degree family history of colorectal, prostate, or breast cancer should avoid IGF-1-elevating protocols. A meta-analysis in The Lancet (N=approximately 115,000 across 8 cohorts) found that individuals in the top quartile of circulating IGF-1 had a relative risk of 1.28 for colorectal cancer compared to the bottom quartile (P<0.001) [10].

People with type 2 diabetes or fasting glucose above 100 mg/dL face real risk of glycemic deterioration with MK-677. The 2-year hip-fracture trial documented meaningful increases in fasting glucose at 25 mg MK-677 [6]. Metformin co-administration may partially mitigate this, but has not been formally studied in this context.

Active fluid retention disorders, heart failure, or significant hypertension are relative contraindications to MK-677 given its sodium-retaining properties.

Age below 25 years is a relative contraindication for exogenous GH-axis manipulation because the growth plates may not be fully fused and endogenous GH pulsatility is already high in young adults [9].

Evidence Gaps and What Research Would Actually Answer the Key Questions

The evidence base for this stack has real, specific holes that practitioners and patients should understand before proceeding.

The most important gap is the absence of any pharmacokinetic interaction study between TB-500 and MK-677. It is not known whether simultaneous administration changes the half-life, tissue distribution, or receptor occupancy of either compound. TB-500's plasma half-life in humans is not well characterized; MK-677 has a half-life of approximately 4 to 6 hours in humans [4].

A second gap is the lack of any human RCT measuring the musculoskeletal outcomes that practitioners most frequently target with this stack, tendon repair speed, return-to-training timelines, or muscle cross-sectional area recovery after injury. The closest data come from animal models. A rodent study showed that thymosin beta-4 combined with GH signaling produced additive increases in myosatellite cell proliferation [7], but this has not been replicated in controlled human trials.

Third, long-term safety data beyond 2 years for MK-677 are absent, and safety data for extended TB-500 use in humans are essentially nonexistent.

The HealthRX medical team recommends that any physician considering this stack for a patient treat the 12-week loading-plus-maintenance protocol as an investigational approach requiring documented informed consent, baseline and 4-week lab monitoring, and a clearly defined decision rule for discontinuation if IGF-1 exceeds the age-adjusted upper reference range or fasting glucose rises above 110 mg/dL on two consecutive measurements.

Key Quotations from Guideline and Clinical Sources

The Endocrine Society's 2019 clinical practice guideline on growth hormone deficiency in adults states: "We suggest against using GH secretagogues for the treatment of GHD in adults outside of formal research studies, due to insufficient evidence of safety and efficacy." [9] While MK-677 is not the same as GH itself, the guideline's caution about secretagogue use outside supervised research directly applies to MK-677 stacks.

Regarding IGF-1 monitoring, the same guideline specifies: "Serum IGF-1 should be maintained within the age- and sex-adjusted normal range during GH replacement therapy." [9] Practitioners using MK-677 to raise IGF-1 should apply this same ceiling.